MalariaPhase 1NCT06607003
Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
A Phase 1 study testing P. vivax challenge agent derived from PvHMB-CCE001 in people with Malaria, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in United States.
Trial summary
Background: Malaria is a disease caused by parasites transmitted to people by mosquitoes. Around the world, there were 241 million cases and 627,000 deaths from malaria in 2020. Researchers are working to develop vaccines and treatments for this disease. Read more about this study
- Who is it for?
- Ages 18 to 54 yearsHealthy volunteers can take part
- Conditions the study is for
- Malaria
- What is being tested?
- P. vivax challenge agent derived from PvHMB-CCE001
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 300 participants
- Where
- 1 siteUnited States
- Study dates
- 26 Nov 2024to 26 Nov 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 54 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- All of the following criteria must be fulfilled for a participant to undergo IBSM:
- Age >=18 and <=54 years.
- RBCs positive for Duffy antigen/chemokine receptor.
- Malaria comprehension exam passed prior to study activities.
- Suitable accommodation and reliable access to the NIHCC for the duration of the study in the opinion of the investigator.
- Persons of childbearing potential must be willing to use reliable contraception from 28 days prior to challenge agent administration to the end of study.
Show all 9Show fewer
- Signing of the informed consent form.
- Agreement to not live alone from challenge agent administration until the completion of antimalarial treatment.
- Agreement to long-term storage of study samples for future research.
Who cannot join
- A participant will be excluded from participating in this trial if any 1 of the following criteria is fulfilled:
- Planned travel to a P. vivax-endemic area during the study period (see https://www.cdc.gov/malaria/travelers/country_table/a.html).
- History of travel to or residence in a P. vivax malaria-endemic region for more than 2 weeks during the past 2 years.
- Prior confirmed P. vivax malaria diagnosis or clinical history consistent with likely P. vivax infection. At the investigator's discretion, participants may be enrolled if the exposure was remote, e.g., > 5 years ago.
- Poor peripheral venous access, at the discretion of the investigator.
- For persons of childbearing potential:
Show all 30Show fewer
- Currently pregnant or breastfeeding, or planning on becoming pregnant or breastfeeding until the end of study.
- Rh blood group negative.
- Being a current or former study team member or clinical trial staff with direct involvement of the trial, or being an employee supervised by a study team member.
- Unwillingness to defer blood donations for at least 3 years.
- Use of any of the following within the specified periods:
- Investigational P. vivax vaccine within the last 2 years.
- Malaria chemoprophylaxis within 3 months of Day 0.
- Chronic systemic immunosuppressive medications (>14 days) within 6 months (e.g., cytotoxic medications, adrenocorticotrophic hormone, or oral/parental corticosteroids equivalent to >0.5 mg/kg/day of prednisone). Corticosteroid nasal spray for allergic rhinitis and topical corticosteroids for mild, uncomplicated dermatitis are allowed.
- Prior receipt of packed red cells or other blood products or immunoglobulins within the previous 6 months.
- Systemic antibiotics or medications with potential antimalarial effects less than 28 days before Day 0 (e.g., clindamycin, chloroquine, benzodiazepines, tetracycline, azithromycin, or doxycycline).
- Investigational product or vaccine less than 28 days before Day 0.
- Receipt of any vaccination less than 28 days before Day 0.
- Current or planned use of medications known to significantly prolong the QT interval or otherwise interfere with study agents.
- Smoking more than 5 cigarettes or equivalent per day and unable to stop smoking for the duration of admission. Participants may smoke up to 5 cigarettes or equivalent per day for the rest of the study (by attestation).
- History of alcohol use disorder (exceptions may be made at the investigator's discretion if they have completed treatment or are otherwise currently abstinent) or refusal to agree to refrain from drinking from the day of the challenge agent inoculation until completion of their antimalarial course.
- Clinically significant medical condition, physical examination findings, other clinically significant abnormal laboratory results, or past medical history including:
- Immunodeficiency including asplenia or functional asplenia or significant autoimmune disease.
- Retinal disease, visual field changes, psoriasis, porphyria, or known allergy to chloroquine or artemether/lumefantrine.
- Cardiac disease including >10% cardiovascular risk as determined by the non-laboratory method or an abnormal EKG demonstrating a corrected QT interval by Fridericia's formula of >450 msec or other concerning arrhythmia.
- Any other medical condition that may have significant implications for current health status and participation in the study, in the opinion of the investigator.
- History of a severe reaction to arthropod bites, or history of anaphylaxis or severe unexpected allergy to any substance.
- Screening blood test or urinalysis laboratory parameters outside of local lab normal range (including infectious serologies). Participants may be included at the investigator's discretion for "not clinically significant" values outside of normal range.
- Any other finding that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a participant's ability to give informed consent, or increase the risk of having an adverse outcome from participating in the study.
- Participants who are determined ineligible to participate for any of the reasons above may be rescreened for eligibility at a later time when the disqualifying condition may be resolved.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
NIH Clinical Center Office of Patient Recruitment (OPR), 800-411-1222 ext. TTY dial 711, ccopr@nih.gov
About this study
Official title: Phase 1 Study of Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
Background:
Malaria is a disease caused by parasites transmitted to people by mosquitoes. Around the world, there were 241 million cases and 627,000 deaths from malaria in 2020. Researchers are working to develop vaccines and treatments for this disease.
Read more
Objective:
To learn how malaria develops in people; how the body's immune system reacts to malaria; and how malaria spreads from people to mosquitoes.
Eligibility:
Healthy people in the Washington DC area, aged 18 to 54 years. They cannot live alone during parts of the study.
Design:
Participants will be infected with a parasite that causes malaria. The parasite will be in donated blood; it will be given through an IV.
Participants will likely develop symptoms within a week after the injection. Researchers will call daily to check on their health. After about 6 days, participants will come to the NIH clinic each day for blood tests.
Participants will check in to the NIH clinic around 10 days after the injection. They will stay in the clinic 3 to 6 days. They will have multiple blood tests every day.
Participants will be bitten by mosquitoes up to 4 times. Cups containing mosquitoes will be held against their skin for 15 minutes.
Participants will begin taking chloroquine close to the end of their clinic stay. Chloroquine is a pill taken by mouth once or twice a day for 3 days. It is FDA-approved to treat malaria.
Participants will have follow-up visits 1 and 3 weeks after discharge.
Read the detailed description
Study Description: Single-center, open-label, phase 1 study to characterize the safety and infectivity of Plasmodium vivax (P. vivax) challenge agent for induced blood-stage malaria (IBSM) in malaria-naive participants at the NIH Clinical Center (NIHCC). Challenge agent derived from a cell bank of cryopreserved blood-stage P. vivax (PvHMB-CCE001) will be administered intravenously. A minimum of 2 participants will undergo IBSM to establish initial safety and infectivity of the challenge agent (pilot group). Additional participants, totaling 10 to 50 (main group), will be enrolled to further develop the model including to evaluate growth kinetics, transmission to mosquitoes using feeding assays and assess the host response to P. vivax infection. All participants who receive challenge agent will undergo antimalarial treatment. Qualification and characterization of the IBSM model, including transmission assays in malaria na(SqrRoot) ve,
unvaccinated participants, is a requisite goal in supporting future studies to evaluate stage-specific vaccines (transmission blocking
vaccines (TBVs) and blood stage vaccines (BSVs)) using the model.
Challenge agent derived from bank PvHMB-CCE001 will be assessed first in a pilot group of at least 2 participants, then subsequently in a main group with participants receiving inoculations in cohorts of up to 10 individuals based on logistical considerations including the capacity of clinic resources. The dose of the challenge agent may be adjusted if needed to generate reliable IBSM.
Objectives:
- Primary Objective --To assess the safety of the P. vivax IBSM model following inoculation of healthy participants.
- Secondary Objectives
- To establish an appropriate challenge agent dose for use in P. vivax IBSM studies.
- To evaluate transmission of P. vivax to vector mosquitoes in the IBSM model by mosquito feeding assays.
- To establish a dataset that may be used as a historical control in future interventional IBSM transmission studies.
- Exploratory Objectives
- To further characterize blood and sexual stage parasite growth profiles following blood-stage P. vivax challenge and treatment.
- To assess host responses to P. vivax IBSM.
- To optimize mosquito infectivity in feeding assays, and study human to mosquito transmission and generate mosquito stages of the parasite.
- To establish a supply of P. vivax infected blood.
Endpoints:
- Primary Endpoint --Incidence and severity of local and systemic adverse events (AEs) or serious adverse events (SAEs).
- Secondary Endpoints
- A suitable dose of challenge agent that generates parasitemia in a reliable and timely manner as determined by the investigator.
- Transmission of P. vivax to Anopheles spp. using mosquito feeding assays including direct feeding assays and/or membrane feeding assays as determined by the detection of oocysts following midgut dissection. Additional optional measures may include salivary gland dissection or detection by molecular methods.
- Demonstration of transmission in mosquito feeding assays among a requisite number of participants.
- Exploratory Endpoints
- Asexual blood-stage and sexual stage parasite growth profiles by quantitative polymerase chain reaction (qPCR) and/or microscopy.
- Antibody responses: Antibody levels elicited following IBSM as measured by enzyme-linked immunosorbent assay (ELISA) (e.g., antibodies against Pvs230, Pvs25, Pvs44/45 sexual stage antigens, or PvMSP3, MSP9, and AMA1 asexual stage antigens), cellular responses, biomarkers, and transcriptional profiling at various timepoints.
- Collection of gametocyte-containing blood and study in mosquito transmission assays.
- Collection of P. vivax-containing blood from participants.
- Conditions
- Malaria
- Being tested
- P. vivax challenge agent derived from PvHMB-CCE001
- Keywords
- IBSM, Challenge, inoculation, Parasitemia, Mosquito Feeding Assay, Malaria Transmission
- Medical subject headings
- Malaria, Parasitemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
P. vivax challenge agent derived from PvHMB-CCE001Biological
- vivax challenge agent derived from PvHMB-CCE001 consists of infected and uninfected erythrocytes stabilized in glycerolyte. Challenge agent derived from this bank consists of thawed, washed, infected and uninfected erythrocytes suspended in injectable-grade normal saline.
| Study group | Role | What they receive |
|---|---|---|
| P. vivax challenge agent derived from PvHMB-CCE001 Main Arm | Experimental | Up to 50 participants will undergo IBSM to further establish safety of the P. vivax challenge agent derived from PvHMB-CCE001 and evaluate transmission to mosquitoes using feeding assays and assess the host response to P. vivax infection. Receives: Biological: P. vivax challenge agent derived from PvHMB-CCE001 |
| P. vivax challenge agent derived from PvHMB-CCE001 Pilot Arm | Experimental | 2 participants will undergo IBSM to establish the safety and infectivity of the P. vivax challenge agent derived from PvHMB-CCE001. Receives: Biological: P. vivax challenge agent derived from PvHMB-CCE001 |
What is being measured
The primary outcome is the main question the study is designed to answer.
To assess the safety of the P. vivax IBSM model following inoculation of healthy participants.
Incidence and severity of local and systemic AEs or SAEs.
Measured: Time of inoculation with the challenge agent until at least 21 days after inpatient discharge
Secondary outcomes (3)
To establish a dataset that may be used as a historical control in future interventional IBSM studies.
Demonstration of transmission in mosquito feeding assays among a requisite number of participants.
Measured: From the time of inpatient admission to the time of discharge.
To evaluate transmission of P. vivax to vector mosquitoes in the IBSM model by mosquito feeding assays.
Transmission of P. vivax to Anopheles spp. using mosquito feeding assays including direct feeding assays and/or membrane feeding assays as determined by the detection of oocysts following midgut dissection. Additional optional measures may include salivary gland dissection or detection by molecular methods.
Measured: From the time of inpatient admission to the time of discharge.
To establish an appropriate challenge agent dose for use in P. vivax IBSM studies.
A suitable dose of challenge agent which generates parasitemia in a reliable and timely manner as determined by the investigator.
Measured: From the time of inoculation until the time of inpatient admission. Expected to be approximately day 9.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Sep 2024
- Study start26 Nov 2024
- Primary completion26 Nov 2027 (estimated)
- Study completion26 Nov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MalariaStudies of the same condition, open and under way.
- More trials run by National Institute of Allergy and Infectious Diseases (NIAID)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
- Investigators
- Joel A Goldberg, M.D., Principal investigator, National Institute of Allergy and Infectious Diseases (NIAID)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06607003
- Sponsor's protocol ID
- 10001970
- Other IDs
- 001970-I
- Status last verified
- 22 Oct 2026
- First submitted
- 20 Sep 2024
- Last updated
- 26 Oct 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided: De-identified data in an NIH-funded or approved public repository.@@@- De-identified data in another public repository.@@@- Identified data in the Biomedical Translational Research Information System (automatic for activities in the CC).@@@- De-identified or identified data with approved outside collaborators under appropriate agreements.@@@- De-identified data in publications and/or public presentations.@@@Data will be shared at the time of or shortly after publication.
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase 1 Study of Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
- ClinicalTrials.gov ID
- NCT06607003
- Acronym / sponsor ID
- 10001970
- Conditions
- Malaria
- Keywords
- IBSM, Challenge, inoculation, Parasitemia, Mosquito Feeding Assay, Malaria Transmission
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)US National Institutes of Health
- Study start
- 26 Nov 2024 (actual)
- Primary completion
- 26 Nov 2027 (estimated)
- Study completion
- 26 Nov 2027 (estimated)
- First posted
- 23 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background:
Malaria is a disease caused by parasites transmitted to people by mosquitoes. Around the world, there were 241 million cases and 627,000 deaths from malaria in 2020. Researchers are working to develop vaccines and treatments for this disease.
Objective:
To learn how malaria develops in people; how the body's immune system reacts to malaria; and how malaria spreads from people to mosquitoes.
Eligibility:
Healthy people in the Washington DC area, aged 18 to 54 years. They cannot live alone during parts of the study.
Design:
Participants will be infected with a parasite that causes malaria. The parasite will be in donated blood; it will be given through an IV.
Participants will likely develop symptoms within a week after the injection. Researchers will call daily to check on their health. After about 6 days, participants will come to the NIH clinic each day for blood tests.
Participants will check in to the NIH clinic around 10 days after the injection. They will stay in the clinic 3 to 6 days. They will have multiple blood tests every day.
Participants will be bitten by mosquitoes up to 4 times. Cups containing mosquitoes will be held against their skin for 15 minutes.
Participants will begin taking chloroquine close to the end of their clinic stay. Chloroquine is a pill taken by mouth once or twice a day for 3 days. It is FDA-approved to treat malaria.
Participants will have follow-up visits 1 and 3 weeks after discharge.
Detailed description
Study Description: Single-center, open-label, phase 1 study to characterize the safety and infectivity of Plasmodium vivax (P. vivax) challenge agent for induced blood-stage malaria (IBSM) in malaria-naive participants at the NIH Clinical Center (NIHCC). Challenge agent derived from a cell bank of cryopreserved blood-stage P. vivax (PvHMB-CCE001) will be administered intravenously. A minimum of 2 participants will undergo IBSM to establish initial safety and infectivity of the challenge agent (pilot group). Additional participants, totaling 10 to 50 (main group), will be enrolled to further develop the model including to evaluate growth kinetics, transmission to mosquitoes using feeding assays and assess the host response to P. vivax infection. All participants who receive challenge agent will undergo antimalarial treatment. Qualification and characterization of the IBSM model, including transmission assays in malaria na(SqrRoot) ve,
unvaccinated participants, is a requisite goal in supporting future studies to evaluate stage-specific vaccines (transmission blocking
vaccines (TBVs) and blood stage vaccines (BSVs)) using the model.
Challenge agent derived from bank PvHMB-CCE001 will be assessed first in a pilot group of at least 2 participants, then subsequently in a main group with participants receiving inoculations in cohorts of up to 10 individuals based on logistical considerations including the capacity of clinic resources. The dose of the challenge agent may be adjusted if needed to generate reliable IBSM.
Objectives:
- Primary Objective --To assess the safety of the P. vivax IBSM model following inoculation of healthy participants.
- Secondary Objectives
- To establish an appropriate challenge agent dose for use in P. vivax IBSM studies.
- To evaluate transmission of P. vivax to vector mosquitoes in the IBSM model by mosquito feeding assays.
- To establish a dataset that may be used as a historical control in future interventional IBSM transmission studies.
- Exploratory Objectives
- To further characterize blood and sexual stage parasite growth profiles following blood-stage P. vivax challenge and treatment.
- To assess host responses to P. vivax IBSM.
- To optimize mosquito infectivity in feeding assays, and study human to mosquito transmission and generate mosquito stages of the parasite.
- To establish a supply of P. vivax infected blood.
Endpoints:
- Primary Endpoint --Incidence and severity of local and systemic adverse events (AEs) or serious adverse events (SAEs).
- Secondary Endpoints
- A suitable dose of challenge agent that generates parasitemia in a reliable and timely manner as determined by the investigator.
- Transmission of P. vivax to Anopheles spp. using mosquito feeding assays including direct feeding assays and/or membrane feeding assays as determined by the detection of oocysts following midgut dissection. Additional optional measures may include salivary gland dissection or detection by molecular methods.
- Demonstration of transmission in mosquito feeding assays among a requisite number of participants.
- Exploratory Endpoints
- Asexual blood-stage and sexual stage parasite growth profiles by quantitative polymerase chain reaction (qPCR) and/or microscopy.
- Antibody responses: Antibody levels elicited following IBSM as measured by enzyme-linked immunosorbent assay (ELISA) (e.g., antibodies against Pvs230, Pvs25, Pvs44/45 sexual stage antigens, or PvMSP3, MSP9, and AMA1 asexual stage antigens), cellular responses, biomarkers, and transcriptional profiling at various timepoints.
- Collection of gametocyte-containing blood and study in mosquito transmission assays.
- Collection of P. vivax-containing blood from participants.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| P. vivax challenge agent derived from PvHMB-CCE001 Main Arm | Experimental | Biological: P. vivax challenge agent derived from PvHMB-CCE001Up to 50 participants will undergo IBSM to further establish safety of the P. vivax challenge agent derived from PvHMB-CCE001 and evaluate transmission to mosquitoes using feeding assays and assess the host response to P. vivax infection. |
| P. vivax challenge agent derived from PvHMB-CCE001 Pilot Arm | Experimental | Biological: P. vivax challenge agent derived from PvHMB-CCE0012 participants will undergo IBSM to establish the safety and infectivity of the P. vivax challenge agent derived from PvHMB-CCE001. |
Who may qualify
- Ages
- 18 to 54 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (9 listed)
- Age >=18 and <=54 years.
- RBCs positive for Duffy antigen/chemokine receptor.
- Malaria comprehension exam passed prior to study activities.
- Suitable accommodation and reliable access to the NIHCC for the duration of the study in the opinion of the investigator.
- Persons of childbearing potential must be willing to use reliable contraception from 28 days prior to challenge agent administration to the end of study.
Key exclusion criteria (30 listed)
- A participant will be excluded from participating in this trial if any 1 of the following criteria is fulfilled:
- Planned travel to a P. vivax-endemic area during the study period (see https://www.cdc.gov/malaria/travelers/country_table/a.html).
- History of travel to or residence in a P. vivax malaria-endemic region for more than 2 weeks during the past 2 years.
- Prior confirmed P. vivax malaria diagnosis or clinical history consistent with likely P. vivax infection. At the investigator's discretion, participants may be enrolled if the exposure was remote, e.g., > 5 years ago.
- Poor peripheral venous access, at the discretion of the investigator.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| P. vivax challenge agent derived from PvHMB-CCE001P. vivax challenge agent derived from PvHMB-CCE001 consists of infected and uninfected erythrocytes stabilized in glycerolyte. Challenge agent derived from this bank consists of thawed, washed, infected and uninfected erythrocytes suspended in injectable-grade normal saline. | Biological | P. vivax challenge agent derived from PvHMB-CCE001 Main Arm, P. vivax challenge agent derived from PvHMB-CCE001 Pilot Arm |
Primary outcome
To assess the safety of the P. vivax IBSM model following inoculation of healthy participants.
Time frame: Time of inoculation with the challenge agent until at least 21 days after inpatient discharge
Incidence and severity of local and systemic AEs or SAEs.
3 secondary outcomes
To establish a dataset that may be used as a historical control in future interventional IBSM studies.
Time frame: From the time of inpatient admission to the time of discharge.
To evaluate transmission of P. vivax to vector mosquitoes in the IBSM model by mosquito feeding assays.
Time frame: From the time of inpatient admission to the time of discharge.
To establish an appropriate challenge agent dose for use in P. vivax IBSM studies.
Time frame: From the time of inoculation until the time of inpatient admission. Expected to be approximately day 9.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
- NIH Clinical Center Detailed Web PageLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided. De-identified data in an NIH-funded or approved public repository.@@@- De-identified data in another public repository.@@@- Identified data in the Biomedical Translational Research Information System (automatic for activities in the CC).@@@- De-identified or identified data with approved outside collaborators under appropriate agreements.@@@- De-identified data in publications and/or public presentations.@@@Data will be shared at the time of or shortly after publication.
Related trials for Malaria
Active, not recruitingObservational study
Trajectories and Mechanisms of Recovery From Malaria: An Observational Study
Malaria
Not yet recruiting
Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection
Healthy Volunteer, Malaria
Recruiting
The Effects of Iron Treatment on Vaccine Immunogenicity in Kenyan Infants With Iron Deficiency
Iron Deficiencies
RecruitingObservational study
Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali
Malaria
RecruitingPhase 1
Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults
Malaria Falciparum
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Joel A Goldberg, M.D. principal investigator
National Institute of Allergy and Infectious Diseases (NIAID)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing P. vivax challenge agent derived from PvHMB-CCE001 in people with Malaria, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Joel A Goldberg, M.D. ((240) 292-4138, joel.goldberg@nih.gov), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To assess the safety of the P. vivax IBSM model following inoculation of healthy participants. (time frame: Time of inoculation with the challenge agent until at least 21 days after inpatient discharge). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.